|Bid||0.4050 x 1200|
|Ask||0.4200 x 3100|
|Day's Range||0.4000 - 0.4291|
|52 Week Range||0.3800 - 1.7500|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.00|
Subscribe to Yahoo Finance Plus to view Fair Value for HOTH
Hoth Therapeutics, Inc. (Nasdaq: HOTH) ("Hoth" or the "Company") today announced that the Company received confirmation from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") notifying the Company that Nasdaq has granted the Company an additional 180-day compliance period, or until December 26, 2022, to regain compliance with Nasdaq's minimum $1.00 closing bid price per share requirement (the "Additional Compliance Period").
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced it has received approval by the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate the next phase of its BioLexa trial for patients suffering with Atopic Dermatitis.
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that its Annual Meeting of Shareholders scheduled for and convened on June 15, 2022 (the "Annual Meeting") was adjourned until 12:00 p.m. Eastern Time on June 23, 2022 to allow additional time to solicit proxies and obtain a quorum for the Annual Meeting. No business other than the adjournment was conducted on June 15, 2022. The Annual Meeting to be held on June 23, 2022 will be held virtually at